ATS 2019 Virtual Final Program

9:35 EVs as Mediators of HIV Mediated Pulmonary Vascular Injury N.K. Dhillon, PhD, Kansas City, KS Parker B. Francis Speaker 9:55 EVs and Death of Endothelium in Sepsis Mediated Acute Lung Injury A. Sarkar, PhD, Columbus, OH 10:15 Airway Exosomes and T helper Responses in Asthma J. Deshane, PhD, Birmingham, AL 10:35 The Dichotomy of the Innate Immune Responses to Exosomes: Implications for Cancer O. Volpert, PhD, Houston, TX 10:55 Circulating Exosomes in Sleep Apnea: Immune (De) Regulators? D. Gozal, MD, MBA, ATSF, Columbia, MO BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 D8 ENVIRONMENTAL EXPOSURES, THE HUMAN MICROBIOME, AND LUNG DISEASE Assembly on Environmental, Occupational and Population Health 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A Two (Level 2) Target Audience Trainees, clinicians, researchers, allied health personnel Objectives At the conclusion of this session, the participant will be able to: • learn new findings about the interaction between environmental exposures, the microbiome, and lung disease; • understand principles of microbial ecology research using sequencing of microbial genes; • obtain new skills to interpret literature on the microbiome and lung disease. There has been intense interest in how the human microbiome leads to, protects against, or modulates the development of lung disease. We are just beginning to understand the interactions between environmental exposures and the human microbiome, with the realization that while exposures may modify the human microbiome, the human microbiome can also modulate the effect of potentially harmful environmental exposures on health. Because of the broad effect of environmental exposures on the human microbiome during early life when the human microbiome is established, further work in this area may have broad implications for development of chronic lung disease. This symposium will highlight recent research focused on microbes, the environment, and lung disease. Chairing: T.D. LeVan, PhD, Omaha, NE P.S. Lai, MPH, MD, Boston, MA E. Von Mutius, MD, MS, Muenchen, Germany 9:15 Historical Perspective of the Human Microbiome T.D. LeVan, PhD, Omaha, NE 9:25 The Impact of Diet on Immunity and Respiratory Diseases P. Hansbro, PhD, Newcastle, Australia 9:45 Ecological Networking of Lung Infections and Targeted Antibiotic Treatment: A Cystic Fibrosis Framework F. Rohwer, PhD, San Diego, CA 10:05 Effect of Air Pollution on the Human Microbiome and Lung Disease R.P. Dickson, MD, Ann Arbor, MI 10:25 The Home Microbiome, Gut Microbiome, and Asthma Susceptibility E. Von Mutius, MD, MS, Muenchen, Germany 10:45 Workplace Animal Exposures and the Human Microbiome P.S. Lai, MPH, MD, Boston, MA 11:05 Panel Discussion TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 D9 HOST DIRECTED THERAPY FOR TUBERCULOSIS: THEORY AND CURRENT EVIDENCE Assembly on Pulmonary Infections and Tuberculosis 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A Three (Level 2) Target Audience Physicians, immunologists, TB researchers, and global health specialists Objectives At the conclusion of this session, the participant will be able to: • introduce the rationale of host directed therapy to researchers and cliniciansChange affected: to stimulate further basic and clinical research in HDT for TB; • understand the epidemiological and experimental evidence supporting the use of specific HDT agents Change affected: to stimulate observational and laboratory studies on the use of well-established HDT agents; • explore applications of HDT for TB, such as MDR-TB treatment shortening, and to encourage broader application of HDT for TB, to prevent TB in exposed persons. This symposium will review the theory and evidence supporting host directed therapy to shorten therapy in drug resistant TB, reduce tissue destruction, and possibly prevent infection, reinfection, or reactivation of infection. The latter application may have a role in protecting healthcare workers exposed to drug resistant TB and for those providing palliative care for drug resistant treatment failures. Remarkably, several widely used, FDA approved agents, such as metformin and statins appear highly active in modifying TB pathogenesis. Future directions toward precision medicine will be discussed. Chairing: R. Hafner, MD, Bethesda, MD E.A. Nardell, MD, Boston, MA 9:15 Current and Future Host Directed Therapies: Toward Precision Medicine R. Hafner, MD, Bethesda, MD 9:35 Role of the Macrophage and Innate Immunity in HDT J.M. Keane, MD, Dublin, Ireland ATS 2019 • Dallas, TX 316 WEDNESDAY • MAY 22